NephroGenex — Investor Presentation (November 2015)
40 slides from NephroGenex's investor presentation, Nov 12, 2015
Slide 1: Corporate Presentation November 2015
Corporate Presentation November 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec
Slide 3: NephroGenex Investment Thesis
NephroGenex Investment Thesis 3 Diabetic nephropathy is a major unmet need with a significant healthcare financial burden Pharmaceutical company developing therapies that target the underlying cause of kidney disease Oral Pyridorin – for the prevention or slowing the progression of diabetic nephro
Slide 4: NephroGenex Team
NephroGenex Team Member Previous Affiliations/Positions Pierre Legault, Chief Executive Officer and President Sanofi-Aventis, President Worldwide Dermatology Eckerd, President Rite Aid, CAO OSI Pharmaceuticals, CFO Prosidion Ltd, CEO Board Member, NPS, Iroko, Tobira, Cyclacel, Forest Labs, others Dr
Slide 5: NephroGenex Pipeline
NephroGenex Pipeline Clinical Program Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral dosing that targets the underlying metabolic pathophysiology of diabetic nephrop
Slide 6: Oral Pyridorin – Significant Market Potential
Oral Pyridorin – Significant Market Potential 6 Diabetic nephropathy progresses from microalbuminuria to macroalbuminuria, then to end stage renal disease (ESRD) and dialysis Estimated 31 million diabetics in the U.S. – 22 million diagnosed, 40% of whom exhibit kidney disease (France, Germany, and U
Slide 7: Pathophysiology of Diabetic Complications
7 Pathophysiology of Diabetic Complications
Slide 8: Pyridorin – Mechanism of Action
8 Pyridorin – Mechanism of Action
Slide 9: Preclinical Overview: Pyridoxamine in Models of DN
9 Other models: Db/db diabetic mouse model of type 2 diabetic nephropathy 1 KK-A(y)/Ta diabetic mouse model of type 2 diabetic nephropathy 2 Obese Zucker fa/fa rat model of metabolic syndrome early nephropathy 3 Preclinical Overview: Pyridoxamine in Models of DN Control rats +/– pyridoxamine U
Slide 10: Clinical Overview: Ph2 Data in Target Ph3 Population
10 Clinical Overview: Ph2 Data in Target Ph3 Population (Type 2 Diabetes; SCr 1.3-3 mg/dL; Urinary Protein >1200 mg/g Cr; Stable SOC)
Slide 11: Preclinical and Clinical Safety Profile
11 Preclinical No toxicity signal in multiple species: ― rabbits - 50X human blood level ― rats - 100X human blood level; 80X human blood level for 6 months ― dogs - 13X human blood level for 12 months ― no signs of intolerance, toxicity or behavioral changes at doses of 50, 100 and 200 mg/kg in a
Slide 12: Pyridorin Development Program
12 Target Indication: Prevention or slowing the progression of diabetic nephropathy with type 2 diabetes Program: Two identical, double-blind Phase 3 studies of 600 patients each Regulatory Agreements: FDA Special Protocol Assessment New endpoint of 50% increase in serum creatinine (decrease
Slide 13: Overview of Phase 3 Study - PIONEER
Objective: Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population: Type 2 diabetic patients Baseline SCr greater than 1.3 and less than 3.0 mg/dL (eGFR > 20 ml
Slide 14: PIONEER Primary and Secondary Endpoints
Primary Endpoints: Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: ― A serum creatinine (SCr) increase of ≥50
Slide 15: PIONEER Phase 3 Interim Analysis
PIONEER Phase 3 Interim Analysis 15 DSMB: Monitoring unblinded safety information on an ongoing basis Interim Analysis 1* (mid-2016): Independent biostatistician will undertake an interim analysis when at least 150 patients have completed a minimum of 12 months on treatment Interim Analysis 2* (
Slide 16: Summary of Phase 2 Data
Summary of Phase 2 Data
Slide 17: Clinical Overview: Ph2 Data in Target Ph3 Population
17 Clinical Overview: Ph2 Data in Target Ph3 Population (Type 2 Diabetes; SCr 1.3-3 mg/dL; Urinary Protein >1200 mg/g Cr; Stable SOC)
Slide 18: PYR-206 – 24 Week Phase 2a Study (50 mg BID)
18 PYR-206 – 24 Week Phase 2a Study (50 mg BID) PYR-206 Multi-center, randomized, double-blind, placebo- controlled trial to assess safety, tolerability and biological activity: N = 128 Population: Type 1 or type 2 diabetes ― Baseline SCr ≤ 2.0 mg/dL ― Urinary Protein: Creatinine Ratio (PCR) >30
Slide 19: Phase 2a PYR-206 Post-hoc Analysis
NephroGenex 6 Month Phase 2a PYR-206 Post-hoc Analysis Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Treatment Effect P value All Patients 65, 63 1.27 0.34 1.33 0.38 0.12 0
Slide 20: PYR-205/207 – 24 Week Phase 2a Study (250 mg BID)
20 PYR-205/207 – 24 Week Phase 2a Study (250 mg BID) PYR-205/207 Multi-center, randomized, double- blind, dose-escalating, placebo- controlled trial to assess safety, tolerability and biological activity: N = 84 Population: Type 1 or type 2 diabetes ― SCr ≤ 2.0 mg/dL (PYR- 205); ― SCr >2 mg/dL a
Slide 21: Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis
NephroGenex 6 Month Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure control Pyridorin at a 250 mg bid dose is well tolerated and slows
Slide 22: PYR-210 – 52 Week Study - Baseline Characteristics
22 PYR-210 – 52 Week Study - Baseline Characteristics
Slide 23: PYR-210 – 52 wk Phase 2b study in Type 2 Diabetes
23 PYR-210 – 52 wk Phase 2b study in Type 2 Diabetes with Overt Nephropathy (150 mg bd and 300 mg bd) PYR-210 Multi-center, randomized, double-blind, placebo- controlled trial to assess safety, tolerability and biological activity: N = 317 Population: Type 2 diabetes with overt nephropathy ― Bas
Slide 24: Phase 2b PYR-210 Pre-Specified Analysis: SOC vs. Non-SOC
NephroGenex 12 Month Phase 2b PYR-210 Pre-Specified Analysis: SOC at Screening vs. Non-SOC at Screening Patients analysis Type 2 Diabetic Nephropathy Patients With and Without SOC1 at screening – 300 and 150 mg bid 1 SOC: ACEI/ARB therapy and blood pressure control. Patients not on SOC at screening
Slide 25: Phase 2b PYR-210 Blood Pressure Changes of SOC vs. Non-SOC
NephroGenex 12 month Phase 2b PYR 210 Blood Pressure Changes of SOC vs. Non-SOC at Screening analysis 25 Patients not on SOC at screening exhibited: higher starting blood pressures, more frequent BP medication changes, and a reduction in BP during the treatment period all of which confounded S
Slide 26: PYR-210 – 52wk Phase 2b Study: Established SOC vs not on SOC
PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients vs not on SOC 26 2 2.2 2.4 2.6 2.8 0 4 12 26 39 52 SOC Placebo SOC 150 mg SOC 300 mg Run-in Placebo Run-in 150 mg Run-in 300 mg Weeks M ean S C r (m g /d L )
Slide 27: Phase 2b ACEI/ARB and Blood Pressure Medication Changes
NephroGenex 12 month Phase 2b PYR 210 ACEI/ARB and Blood Pressure Medication Changes Prior to Randomization analysis 27 F re q u e n c y % Run-in Start of Trial - 6 mo F re q u e n c y % - 12 mo Established SOC - 9 mo - 3 mo Start of Trial - 6 mo -12 mo or earlier - 9 mo - 3 mo 60 20 60 20 40 40 Non
Slide 28: Importance of Stable Standard of Care in DN trials
28 Importance of Stable Standard of Care in DN trials
Slide 29: Importance of Stable Standard of Care in DN trials
29 The FDA is aware of this observed effect and requires sponsors to account for possible acute changes in SCr arising from ACEi/ARB/BP medication changes that could impact the SCr baseline and SCr-based calculated treatment effects. A pre-specified analysis was included in the Phase 2b Statisti
Slide 30: PYR-210 – Post-hoc analysis with Phase 3 endpoint
30 PYR-210 – Post-hoc analysis with Phase 3 endpoint
Slide 31: Pyridorin Safety Profile: PYR-210
Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of 300 mg BID Pyridorin Safety Profile: PYR-210 31 Most Reported Adverse Events Most Reported Serious Adverse Events No meaningful differences between groups
Slide 32: Acute Kidney Injury - IV Pyridorin
Acute kidney injury (AKI) is a serious medical problem that results in substantial morbidity, prolonged hospitalization, increased medical costs, and significant mortality The major causes of hospital-acquired AKI are decreased renal perfusion during surgery, contrast nephropathy and cancer ther
Slide 33: AKI - Ischemia-reperfusion (I/R) Model
33 PYR treatment was provided to mice in drinking water starting 72 h prior to injury and continued until sacrificed. AKI - Ischemia-reperfusion (I/R) Model NF = nephrectomy
Slide 34: Exclusivity Patents and New Chemical Entity (NCE)
No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S. Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension) Method of manufacture patent February 2025 NCE - 5 year exclu
Slide 35: NephroGenex Milestones
NephroGenex Milestones 35 Achieved Expected Feb-2014 Completion of Initial Public Offering Mar-2014 Secured CRO June-2014 Enrolled first patient in PIONEER pivotal Phase 3 trial Nov-2014 Publication on new endpoint Nov-2014 Poster presentations at American Society of Nephrology Dec-2014
Slide 36: Financial Snapshot
Financial Snapshot Cash As of September 30, 2015, approximately $20.9 million in cash, cash equivalents and investments Raised an additional $5.0 million of net proceeds from a PIPE in November 2015 Sufficient cash balance to finance operations into mid-2016 NASDAQ: NRX (as of November 9, 2015
Slide 37: Corporate Summary
Corporate Summary 37 Diabetic nephropathy is a major unmet need with a significant healthcare financial burden Pharmaceutical company developing therapies that target the underlying cause of kidney disease Oral Pyridorin – for the prevention or slowing the progression of diabetic nephropathy in pa
Slide 38: Appendix
Appendix
Slide 39: Serum Creatinine and eGFR Definitions
Definition Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Compar
Slide 40: Key Milestone: NKF/FDA Workshop
40 Key Milestone: Dec 3-4 2012 NKF/FDA Workshop A doubling of serum creatinine is generally a late event in CKD and takes a long time to develop There is great interest in considering alternative endpoints for clinical trials: to shorten the duration of clinical trials to extend their applicatio